SAN DIEGO, March 14 /PRNewswire-FirstCall/ -- Cardium Therapeutics
(Amex: CXM) today reported highlights and financial results for its fiscal
year ended December 31, 2007, and other important recent developments.
Highlights and Recent Developments
-- Initiation of Phase 2b MATRIX clinical trial to evaluate the safety
and efficacy of Excellarate(TM) for the potential treatment of
non-healing diabetic foot ulcers. Excellarate is a DNA-based topical
gel that is being developed to be administered once or twice to
stimulate wound healing. The MATRIX study, a randomized,
double-blind, placebo-controlled, comparator arm clinical trial is
expected to enroll approximately 210 patients at about 30 U.S. sites.
Top line safety and efficacy data from the trial is expected to be
announced in late 2008.
-- Initiation of Phase 3 AWARE trial for Generx(TM), a randomized,
placebo-controlled, double-blind clinical trial that is expected to
enroll approximately 300 women at an estimated 50 U.S. medical
centers. Generx is being evaluated as a potential treatment for
myocardial ischemia (insufficient blood flow within the heart muscle)
which gives rise to angina associated with coronary heart disease.
The U.S. Food and Drug Administration (FDA) has granted Fast Track
designation to Generx for myocardial ischemia in view of the large
unmet medical need for effective new therapies to treat coronary heart
|SOURCE Cardium Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved